[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100406641":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":23,"locations":34,"responsibleParty":74,"collaborators":78,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":23,"eligibilityCriteria":89,"healthyVolunteers":86,"sex":90,"minAge":91,"maxAge":23,"enrollmentInfo":92,"targetDuration":23,"studyType":95,"phases":96,"briefSummary":99,"conditions":100,"keywords":23,"overallStatus":104,"whyStopped":105,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Klinikum Bremen-Mitte, gGmbH","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Standard of Care (SoC)","This arm will receive standard supportive care according to guidelines for COVID-19. This is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.",[12],"Other: Standard of Care (SoC)",{"label":14,"type":15,"description":16,"interventionNames":17},"Remdesivir + SoC","EXPERIMENTAL","Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care",[12,18],"Drug: Remdesivir",[20,24],{"type":6,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.",[14,9],null,{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":23},"DRUG","Remdesivir","Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first",[14],[30],{"name":31,"affiliation":32,"role":33},"Tobias Welte, MD, Prof.","Hannover Medical School","PRINCIPAL_INVESTIGATOR",[35,47,56,65],{"facility":36,"status":23,"city":37,"state":23,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":23},"Gesundheit Nord gGmbH","Bremen","28211","Germany","DE",{"type":42,"coordinates":43},"Point",[44,45],8.80717,53.07582,{"lat":45,"lon":44},{"facility":48,"status":23,"city":49,"state":23,"zip":50,"country":39,"countryCode":40,"cosmosGeoPoint":51,"geoPoint":55,"contacts":23},"Universitätsklinikum Gießen","Giessen","35392",{"type":42,"coordinates":52},[53,54],8.67554,50.58727,{"lat":54,"lon":53},{"facility":57,"status":23,"city":58,"state":23,"zip":59,"country":39,"countryCode":40,"cosmosGeoPoint":60,"geoPoint":64,"contacts":23},"Medizinische Hochschule Hannover (MHH)","Hanover","30625",{"type":42,"coordinates":61},[62,63],9.73322,52.37052,{"lat":63,"lon":62},{"facility":66,"status":23,"city":67,"state":23,"zip":68,"country":39,"countryCode":40,"cosmosGeoPoint":69,"geoPoint":73,"contacts":23},"Technische Universität München (TUM)","München","81675",{"type":42,"coordinates":70},[71,72],13.31243,51.60698,{"lat":72,"lon":71},{"type":75,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Professor Dr. Bernd Mühlbauer","Professor of Pharmacology - Head of Department",[79,82],{"name":80,"class":81},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"name":83,"class":6},"World Health Organization","100406641","phase-2-an-international-randomized-trial-of-additional-treatments-for-covid-19-in-hospitalized-patients-who-are-all-receiving-the-local-standard-of-care---who-solidarity-germany-100406641",false,"NCT04575064","An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY","Inclusion Criteria:\n\n* Patients 18 years and older\n* Current SARS-CoV-2 infection\n* Admitted to the hospital ward or the ICU due to COVID-19\n* SpO2 \\\u003C= 94% on room air OR oxygen demand OR breathing support\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Patient's non-consent or inability to informed consent\n* Pregnant or breastfeeding women.\n* Subjects pretreated with one of the study drugs in the past 29 days\n* Anticipated transfer within 72 hours to a non-study hospital\n* Severe co-morbidity with life expectancy \\\u003C 3 months\n* AST or ALT \\> 5 times the upper limit of normal\n* Stage 4 severe chronic kidney disease or requiring dialysis\n* Contraindications and known intolerance to any of the study drugs\n* Subjects participating in a potentially confounding drug or device trial\n* Any reason why the patient should not participate (investigator's opinion)","ALL","18 Years",{"count":93,"type":94},0,"ACTUAL","INTERVENTIONAL",[97,98],"PHASE2","PHASE3","This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.",[101,102,103],"SARS-CoV-2 Infection","COVID-19","Moderate and Severe COVID-19","WITHDRAWN","Explanation will be submitted later.","2024-10-07",{"date":108,"type":94},"2024-10-09",{"date":110,"type":94},"2020-06-29",{"date":112,"type":113},"2022-11","ESTIMATED",{"name":76,"class":6},4]